What the US Biosecure Act Means for Chinese Firms
This article is for subscribers only.
Chinese biotechnology firms are seeing the wildest swings in months as investors struggle to assess the impact of a US push to block the Asian nation from developing capabilities in fields ranging from health to technology.
The US House of Representatives on Sept. 9 passed the so-called Biosecure Act that would blacklist Chinese biotech companies and their US subsidiaries from accessing federally-funded contracts. American lawmakers backing the legislation argue that Chinese companies with ties to Beijing could engineer bioweapons or otherwise capitalize on biological data sourced from other countries.